Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response

Tuberculosis, Pulmonary Clinical Trial

— PAT  

Official title:

Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03416309
• Other study ID #: PAT_Study
• Status: Recruiting
• Start date: May 25, 2017
• Est. completion date: February 28, 2022

Study information

• Verified date: April 2019
• Source: University of Turin, Italy
• Contact: Ilaria Motta
• Phone: +390114393856
• Email: ilaria.motta[@]unito.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of the study is to investigate the possible correlation of plasma drug concentrations with Time To Positivity (TTP) in liquid culture in patients with active pulmonary multi sensitive TB in the first two weeks of treatment. Secondary aims are: the correlation between plasma drug concentrations and hepato/neuro toxicity; the impact of different allelic variants on PK data, toxicity and TTP in liquid culture; the feasibility of using dried blood/plasma spots to measure plasma concentrations of anti-TB drugs and determine genetic polymorphisms.

Description:

A longitudinal observational multicentred study will be conducted in patients with diagnosis of active pulmonary TB.

The following variables will be recorded:

• demographic variables: age, gender, ethnicity, SNPs for NAT2, SLCO1B1, ABCB1 and VDR;

• clinical variables: weight, height, renal function tests, liver function tests, vitamin D (25-OH vitamin D) level, albuminemia, serology for HIV, HCV, presence of comorbidities (e.g. diabetes mellitus), visual acuity test, presence of neuropathic symptoms;

• microbiological variables: phenotypic and genotypic drug sensitivity test results, sputum Mycobacterium tuberculosis DNA (PCR), microscopy, culture, Time To Positivity (TTP) in liquid culture, IGRA test (if performed), history of previous treatments, location of pulmonary lesions, presence of extra-pulmonary locations;

• therapeutic variables: start/end of treatment, treatment interruptions, dose mg/kg, route of administration.

The patients will received standard antitubercular drugs according to international guidelines (RIF 10 mg/kg, INH 5 mg/kg maximum dose 300 mg, ETB 15-20 mg/kg, PZA 25 mg/kg maximum dose 2000 mg) in fasten condition, once daily.

To measure plasma concentrations four blood samples (Lithium heparin 7 ml tubes) will be collected at 0, 2, 4 and 6 hours post dose. This analysis will be performed at 7 and 14 days after the beginning of anti-TB treatment.

For the pharmacogenetic analysis a blood sample (EDTA 4 ml tube) will be collected at the baseline.

Sputum samples will be collected at baseline, 7 and 14 days for Mycobacterial culture.

Medical visits and blood samples (for LFTs) will be performed at baseline, 7 and 14 days to investigate neuro and hepato- toxicity.

Pharmacokinetics After the collection the samples will be centrifugated (3000 rev min−1 at 4°C for 10 min) and plasma will be frozen at − 20°C in 2 aliquots (1 mL of volume) and will be delivered to the Laboratory of Pharmacokinetics and Pharmacogenetics of the University of Torino Amedeo di Savoia Hospital, ASLTO2, Torino, Italy.

Plasma concentrations of all four drugs will be measured using liquid chromatography coupled with tandem mass-spectroscopy (allowing high sensitivity despite small sample volumes). Collected concentration-time data will be evaluated by a non-compartmental approach to characterize the pharmacokinetic properties at steady-state. AUC, maximum (Cmax) and minimum (Cmin) drug levels and plasma elimination half-life will be used to assess the enzymatic induction properties of these drugs. Pharmacogenomics (PG) DNA will be extracted from whole blood using QIamp DNA Mini Kit (Quiagen, Valencia, CA). Purified and eluted DNA will be directly used for real-time PCR (BIORAD, Milano, Italia) reaction. The allelic discrimination analysis will be performed using the TaqMan assays (Applied Biosystems, Foster City, CA).

Analyzed SNPs will be:

ABCB1 3435C>T (rs1045642), OATP1B1 521T>C (rs4149056) e OATP1B1 85-7793T>C (rs4149032), PXR 63396C>T (rs2472677), BsmI G>A (rs1544410).

and NAT2 G>A (rs1799930). Dried blood spots (DBSs) and Dried plasma spots (DPSs) Method for the determination of plasma concentrations on DPSs will be developed and validated by our laboratory. In the study, the blood samples for evaluation on DPSs will be obtained only from subjects of our institute. After centrifugation (3000 rev min−1 at 4°C for 10 min) 100 μ l plasma will be spotted onto each glass filter (purchased from Laboratori Biomicron srl, Italy) and used for pharmacokinetic (PK) analysis. The remaining plasma will be used as controls in the analysis.

For the pharmacogenetic (PG) analysis venous blood samples will be obtained from all subjects and whole blood (50 μ l per spot) will be spotted on DBS Whatman 903 protein saver cards (VWR International, Milan, Italy).

DBS will be inserted in a foil bag with desiccant (Foil Bag and Desiccant Packs, purchased from Laboratori Biomicron srl, Italy) and then stored at room temperature. After a maximum of 30 days samples will be delivered to the Laboratory of Pharmacokinetics and Pharmacogenetics of the University of Torino Amedeo di Savoia Hospital, ASLTO2, Torino, Italy. They will be stored at − 20°C until analysis will be performed (within 3 months from collection).

Time To Positivity Time to positivity on sputum cultures at baseline, 7 and 14 days will be calculated using software BD Epicenter integrated in BACTEC MGIT System (Mycobacteria Growth Indication Tube) 960. Default time is 42 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 257
• Est. completion date: February 28, 2022
• Est. primary completion date: February 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• signed informed consent

• age >=18 years;

• pulmonary tuberculosis defined by positive sputum microscopy (waiting for culture confirmation)

• sensitivity to first-line anti-TB drugs;

• normal liver and renal function.

Exclusion Criteria:

• severe malnutrition;

• HIV infection

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Locations

Country	Name	City	State
Italy	Ospedale Amedeo di Savoia	Torino

Sponsors (2)

Lead Sponsor	Collaborator
University of Turin, Italy	Research Center Borstel

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between AUC of RHZE and TTP	Investigate the correlation of plasma drug concentrations (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, HRZE) with the change in Time To Positivity (TTP) in liquid culture in patients with active pulmonary TB between the baseline and the first week of treatment.	1 week from start of treatment
Primary	Correlation between AUC of RHZE and TTP	Investigate the correlation of plasma drug concentrations (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, HRZE) with the change in Time To Positivity (TTP) in liquid culture in patients with active pulmonary TB between the baseline and the second week of treatment.	2 weeks from start of treatment
Secondary	Correlation between AUC of RHZE and toxicity	Investigate the correlation of plasma drug concentrations (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, HRZE) with hepatotoxicity (increase of AST and/or ALT) and neurotoxicity (peripheral neuropathy)	1 week and 2 weeks from start of treatment
Secondary	Correlation between PG and AUC of RHZE	Investigate the impact of different allelic variants of NAT2, SLCO1B1, ABCB1, VDR on AUC of RHZE toxicity and TTP in liquid culture	1 week and 2 weeks from start of treatment
Secondary	Assess the consistency of results using of DPS for measuring the plasma drug concentrations	Assess the consistency of using dried plasma spots to measure plasma concentrations of anti-TB drugs comparing to plasma samples	1 week and 2 weeks from start of treatment
Secondary	Correlate AUC of RHZE with antiTB response	A pharmacometric model will be develop to correlate pharmacokinetics (AUC of RHZE) with the anti-TB treatment response (clinical and TTP) of the standard first-line anti-TB regimen.	6 months after end of treatment
Secondary	Correlate PG with antiTB response	A pharmacometric model will be develop to correlate PG with the anti-TB treatment response (clinical and TTP) of the standard first-line anti-TB regimen.	6 months after end of treatment